Limitations, agreements, and source contact

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers · Source last updated 2022-02-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details

Clinical Study Agreement

pi Sponsor Employee

false

restriction Type

OTHER

restrictive Agreement

true

limitations And Caveats

description

Study enrollment was permanently discontinued on 17 May 2018 as a strategic decision.

point Of Contact

email

medinfo@incyte.com

organization

Incyte Corporation

phone

1-855-463-3463

title

Study Director

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice